Prosecution Insights
Last updated: April 19, 2026
Application No. 18/103,932

IODINATED COMPOUNDS AND HYDROGELS FORMED FROM SAME

Non-Final OA §102§Other
Filed
Jan 31, 2023
Examiner
YOUNG, MICAH PAUL
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BOSTON SCIENTIFIC CORPORATION
OA Round
1 (Non-Final)
55%
Grant Probability
Moderate
1-2
OA Rounds
3y 6m
To Grant
85%
With Interview

Examiner Intelligence

Grants 55% of resolved cases
55%
Career Allow Rate
531 granted / 965 resolved
-5.0% vs TC avg
Strong +30% interview lift
Without
With
+30.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
53 currently pending
Career history
1018
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
55.3%
+15.3% vs TC avg
§102
20.0%
-20.0% vs TC avg
§112
9.7%
-30.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 965 resolved cases

Office Action

§102 §Other
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The information disclosure statement (IDS) submitted on 4/26/23, 5/24/23, 8/20/25, 12/14/25 were filed in a timely manner. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-20 is/are rejected under 35 U.S.C. 102a1 as being anticipated by Delaney, Jr. et al (US 2021/0062004 hereafter Delaney) Delaney discloses a system for forming a hydrogel comprising (a) a first composition that comprises a polyiodinated polyamino compound that comprises polyamino moiety linked to the polyiodinated aromatic moiety by an amide group [0006-0007] and a (b) second composition that is reactive multi-arm polymer that is reactive with the amino groups of the polyiodinated polyamino compound [0008-0010], meeting the limitations of claims 1. The polyiodinated aromatic moiety comprises a multicyclic or monocyclic aromatic substituted with a plurality of iodine groups or hydrophilic functional groups [0035-0036], meeting limitations of claims 2-4. The multicyclic aromatic moiety can be a benzene [0036], meting limitations of claim 5. The polyiodinated aromatic moiety is a 1,3- substituted -2,4,6-triiodobenzene moiety in which a substituent at each of the 3 positions are carboxyl groups such as a polylysine, poly (allyl amine) [0039-40], meeting the limitations of 6-8. The polyamino moiety can include methylamines as well, where the amines are attached along the chain [0061], meeting limitations of claims 9-10. The hydrophilic polymer arms of the second components include ethylene oxide, N-vinyl pyrrolidone, oxazoline [0030] meeting the limitations of claim 11. The electrophilic such as benzene, imidazole carboxylate or imide esters [0017, 0018, 0033], meeting the limitations of claim 12-13. The hydrogel is formed by a method of the above components [0045-0047], meeting limitations of claims 18-20. The hydrogel can be delivered in a medical device [0063], meeting limitations of claim 14. The system for delivery comprises a first reservoir that contains the first composition wherein the during operation the first and second compositions are dispensed from the reservoirs, and where the compositions interact and crosslink, and where the delivery device is a double barrel syringe [0059-0054], meeting the limitations of claims 15-16. These disclosures render the claims anticipated. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICAH PAUL YOUNG whose telephone number is (571)272-0608. The examiner can normally be reached Monday through Friday, 9:00 am to 5:30 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 5712720616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICAH PAUL YOUNG/ Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Jan 31, 2023
Application Filed
Mar 07, 2026
Non-Final Rejection — §102, §Other (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594364
BONE VOID FILLER PREPARATION SYSTEM
2y 5m to grant Granted Apr 07, 2026
Patent 12594250
PREVENTION OF ACCUMULATED TOLERANCE TO STIMULANT MEDICATION FOR THE TREATMENT OF ADHD
2y 5m to grant Granted Apr 07, 2026
Patent 12569557
TARGETING moDC TO ENHANCE VACCINE EFFICACY ON MUCOSAL SURFACE
2y 5m to grant Granted Mar 10, 2026
Patent 12564587
BUPROPION DOSAGE FORMS WITH REDUCED FOOD AND ALCOHOL DOSING EFFECTS
2y 5m to grant Granted Mar 03, 2026
Patent 12551486
NOVEL RIVAROXABAN FORMULATION
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
55%
Grant Probability
85%
With Interview (+30.1%)
3y 6m
Median Time to Grant
Low
PTA Risk
Based on 965 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month